GAINESVILLE, Fla., Nov. 10, 2011 (GLOBE NEWSWIRE) -- Quick-Med Technologies, Inc. (OTCQB:QMDT), a life sciences company that is developing innovative technologies for the healthcare and consumer markets, announced today that the U.S. Patent Office has issued a Notice of Allowance for a key composition of matter patent for its novel polyurethane modified polycation, the newest member of the NIMBUS technology family of antimicrobials. NIMBUS technology encompasses the chemistry of antimicrobials that comprise a high charge density polycation which is built into the backbone of various polymers such as polyurethane in this case.
The forthcoming patent, Disinfectant with Quaternary Ammonium Polymers and Copolymers, covers the incorporation of the polycation into the main chain of the urethane polymer. When issued, it will provide protection for various claims regarding the efficacy and durability of a polyurethane.
Whereas the fundamental NIMBUS technology offers opportunities for antimicrobial applications that employ absorbent substrates, the unique polyurethane polycation adds a new dimension to NIMBUS technology encompassing applications such as films and coatings, adhesives, catheters and other types of extruded tubing, and as a durable hand sanitizer. The physical state of the polyurethane polycation can be modified to alter the strength of the antimicrobial, the breathability of the film or coating and its flexibility or rigidity.
"Our latest Notice of Allowance is strategically important because it significantly expands our proprietary NIMBUS technology," said J. Ladd Greeno, Quick-Med's CEO. "This forthcoming patent protects the underlying chemistry for several of our cutting-edge developments including applications for advanced wound dressings, medical adhesives, and catheters. When commercialized, we believe that these latest developments in our NIMBUS portfolio will benefit patients and medical professionals in a variety of healthcare settings."
NIMBUS technology employs a safe, eco-friendly active agent that remains in full concentration on any of several substrates. It controls a broad range of both Gram-positive and Gram-negative bacteria. The NIMBUS antimicrobial is not depleted in use, maintains effectiveness even in the presence of large amounts of blood or body fluids, and by design, poses no risk of bacteria developing resistance.
NIMBUS non-leaching antimicrobial technology was cleared by FDA in 2009 and is available in the BIOGUARD® barrier dressings from Derma Sciences, Inc. (Nasdaq:DSCI). NIMBUS is the only non-leaching antimicrobial wound dressing and, by design, poses no risk of bacteria developing resistance. NIMBUS technology is protected by ten U.S. patents and patents pending and 24 foreign counterparts.
A Notice of Allowance communicates the Patent Office's determination that the applicant is entitled to a patent under the law. The Company expects the new patent to be issued early in the coming year.
About Quick-Med Technologies, Inc.
Quick-Med Technologies, Inc. is a life sciences company that is developing proprietary, broad-based technologies for infection prevention and control in the healthcare and consumer markets. Quick-Med commercialized its NIMBUS technology in traditional wound care products in 2009 and is developing NIMBUS applications in several other medical device areas including adhesives, foams, hydrogels, films, hydrocolloids, and catheters. Additionally, its new Stay Fresh® technology provides highly durable antimicrobial protection for apparel and other textile applications and its NimbuDerm™ technology is being developed as a long-lasting hand sanitizer. For more information, see: www.quickmedtech.com.
The Quick-Med Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=8260
© 2011 Quick-Med Technologies, Inc. All rights reserved. NIMBUS®, Stay Fresh® and MultiStat® are registered trademarks and NimbuDerm™ is a trademark of Quick-Med Technologies, Inc. BIOGUARD® is a registered trademark of Derma Sciences, Inc.
Forward-looking statements (statements which are not historical facts) in this release are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. For this purpose, any statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may", "will", "to", "expect", "plan", "believe", "anticipate", "intend", "could", "would", "estimate", and/or "continue" or the negative or other variations thereof or comparable terminology are intended to identify forward-looking statements involve risks and uncertainties, including those risks that are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"), which may be accessed at the SEC's Edgar System at www.sec.gov.
CONTACT: Quick-Med Technologies J. Ladd Greeno, CEO (888) 835.2211 Ext 102 firstname.lastname@example.org Stonegate Securities, Inc. Casey Stegman (investor/media contact) (214) 987-4121 email@example.com